Since AML1-ETO expression is critical for t(8;21) AML leukemia, identifying factors that post-transcriptionally regulate AML1-ETO via the ETO 3′UTR may improve our understanding of how AML1-ETO expression is maintained and uncover suitable targets for t(8;21) AML therapy. This evidence concerns the gene RUNX1 and leukemia.